Moderna (NASDAQ:MRNA) Price Target Lowered to $45.00 at JPMorgan Chase & Co.

Moderna (NASDAQ:MRNA) had its price objective reduced by JPMorgan Chase & Co. from $59.00 to $45.00 in a research note published on Tuesday,Benzinga reports. They currently have an underweight rating on the stock.

Several other analysts have also recently issued reports on the stock. Sanford C. Bernstein initiated coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. Bank of America dropped their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. UBS Group decreased their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $83.26.

Moderna Price Performance

Moderna stock opened at $42.05 on Tuesday. The firm has a market capitalization of $16.18 billion, a P/E ratio of -7.23 and a beta of 1.69. Moderna has a one year low of $35.80 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The business has a fifty day moving average price of $54.45 and a 200-day moving average price of $93.15.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the company earned ($1.39) EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. As a group, equities research analysts forecast that Moderna will post -9.44 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 1,609 shares of company stock worth $112,295. 15.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Moderna

Large investors have recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Moderna by 1.4% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock worth $19,239,000 after purchasing an additional 3,978 shares during the period. Toronto Dominion Bank raised its position in Moderna by 23.7% during the 3rd quarter. Toronto Dominion Bank now owns 131,477 shares of the company’s stock valued at $8,787,000 after purchasing an additional 25,177 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after buying an additional 178,115 shares during the period. Groupama Asset Managment grew its position in shares of Moderna by 29.1% in the 3rd quarter. Groupama Asset Managment now owns 21,838 shares of the company’s stock worth $1,459,000 after buying an additional 4,920 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its stake in shares of Moderna by 1.5% during the third quarter. Nomura Asset Management Co. Ltd. now owns 114,335 shares of the company’s stock valued at $7,641,000 after buying an additional 1,635 shares during the period. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.